Table 2.
Main demographic and clinical characteristics of migraine patients enrolled in the study
| Median age [IQ range] (years) | 46 [34–54] |
| Women/Men | 174 (77%) - 51 (23%) |
| Median disease duration [IQ range] (years) | 30 [18–39] |
| Migraine with aura/Migraine without aura | 48 (21%) – 177 (79%) |
| Median monthly headache days [IQ range] | 15 [8–26] |
| Median monthly migraine days [IQ range] | 12 [8–18] |
| Episodic/Chronic migraine | 100 (44%) – 125 (56%) |
| Median of preventive treatments used in the past [IQ range] | 3 [0.5–5] |
| Migraine with medication overuse/ Migraine without medication overuse | 112 (49%) – 113 (51%) |
| Median of monthly tablets of acute treatments [IQ range] | 15 [8–26] |
| Median MIDAS score [IQ range] | 36 [15–89] |
| Median HIT-6 score [IQ range] | 65 [61–68] |
| Median NRS score [IQ range] | 8 [7–8.5] |
| Median ASC-12 score [IQ range] | 4 [1–7] |
Measures are reported as median and interquartile range (25th – 75th percentiles). Sex, type of migraine, presence of aura and medication overuse are reported as frequencies
Abbreviations: ASC-12 Allodynia Symptom Checklist, HIT-6 Headache Impact Test, IQ interquartile range, MIDAS Migraine Disability Assessment Test, NRS Numeric Rating Scale (NRS)